mRNA Innovations
Technology Advances Needed to Drive Future mRNA Growth
Hagen Richter, Ph.D.
PAO-04-24-CL-04Apr 15, 2024
mRNA Manufacturing
Navigating mRNA Manufacturing with Flexibility and Innovation
Michael van der Horst, Ph.D.
PAO-04-24-CL-02Apr 08, 2024
New Integrated mRNA Offering
Building on Experience and Investing in an Integrated mRNA Offering
Jessica Madigan; Normand Blais
BIOVECTRA
PAO-07-23-CL-03Jul 31, 2023
Risk Management in mRNA Manufacture
Managing Risk in Cutting-Edge mRNA Therapeutics
Jessica Madigan; Normand Blais
BIOVECTRA
PAO-07-23-CL-04Jul 31, 2023
mRNA Ultra-Cold Chain Management
Ultra-Cold Chain and Supply Chain Management Strategies for mRNA
Eunseo (Ency) Lee, Ph.D; Jungkeun (Henry) Oh; Hanel Hwang
Samsung Biologics
PAO-02-23-CL-09Mar 09, 2023
mRNA Manufacturing
Investing in the Future of mRNA Manufacturing
Esther Yoo, Ph.D.
Samsung Biologics
PAO-11-022-CL-02Nov 16, 2022
Quality in mRNA Manufacturing
Quality in Equals Quality Out in mRNA Manufacturing
Judith McCorry
Vernal Biosciences
PAO-10-022-CL-08Nov 08, 2022
mRNA Manufacture
Platform Processes and End-to-End Capabilities Position Vernal Biosciences as a Critical CDMO Resource for mRNA Developers
Tonia Becker
Nice Insight
PAO-10-022-CL-03Oct 25, 2022
mRNA Manufacturing
Overcoming Bottlenecks in mRNA Manufacturing
Pierre Catignol; Huisub Lim
Samsung Biologics
PAO-10-022-CL-04Oct 24, 2022
mRNA
Limitless Potential of mRNA Creates Tremendous Excitement Despite Uncertainties
Cynthia A. Challener, Ph.D.
Pharma's Almanac
PAO-10-022-NI-02Oct 11, 2022
Column: M&A
Who's Left to Acquire in CDMO Biomanufacturing? A Select Few.
Nigel Walker
Nice Insight
PAO-06-022--NI-12Jun 24, 2022
mRNA Manufacturing
Vernal Biosciences Raises $21 Million to Accelerate mRNA Manufacturing Growth
Vernal Biosciences
PR-M06-22-01-351Jun 02, 2022
Column: Technology
mRNA Technology: Is the Long Path Behind Leading to Endless Successes Ahead?
Cynthia A. Challener, Ph.D.; David Alvaro, Ph.D.; Danielle Alvarez
Pharma's Almanac
PAO-03-022-NI-02Mar 23, 2022
mRNA
Leveraging Existing Technologies with New Dedicated Facilities for mRNA Projects
Scott Doncaster; Marc Sauer, Ph.D.
BIOVECTRA
PAO-02-022-CL-07Mar 12, 2022
Facility Acquisition
MilliporeSigma Announces Closing of Exelead Acquisition and Plans to Invest More Than € 500 Million in Technology Scale-Up
MilliporeSigma
PR-M02-22-20Feb 23, 2022
CDMO Acquisition
Recipharm Acquires Arranta Bio, a CDMO Leader in Advanced Therapy Medicinal Products (ATMPs), to Expand its Biologics Offering in the U.S.
Recipharm AB
PR-M02-22-17Feb 18, 2022
mRNA Vaccine Manufacturing
Presenting an Integrated Solution for mRNA Vaccine Manufacturing
Mark Bamforth; Dave Stevens
Arranta Bio
PAO-01-22-R250-04Jan 26, 2022
mRNA Manufacturing
Serving an Accelerated Market with mRNA Production
Mark Bamforth
Arranta Bio
PAO-11-21-CL-06Dec 08, 2021
Investing in mRNA Production
Michael Wourms
Arranta Bio
PA766Nov 22, 2021
mRNA Manufacturing
Limiting Risk In mRNA Development and Production
Doug Kennedy
Arranta Bio
PAO-11-21-CL-05Nov 22, 2021